Oxford Gene Technology (OGT), Oxfordshire, UK, has launched SureSeq myPanel next-generation sequencing (NGS) custom cancer panels to provide scientists with completely customized, preoptimized NGS probe panels relevant to their research. The comprehensive library of gene content covers such key cancer types as breast, chronic lymphocytic leukaemia, myeloid, and ovarian cancers. Utilizing hybridization-based capture, the panels are designed to deliver coverage completeness and uniformity, and are regularly updated for maximum relevance to current research. The panels provide uniform coverage through all target regions, including intronic and splice sites, and reduce the need for fill-in Sanger sequencing. For more information, visit OGT.